Most thyroid cancer is curable, and the majority of people diagnosed with it will live full, normal lifespans. The most common type, papillary thyroid cancer, has a five-year survival rate above 99% when all stages are combined. Even at 20 years after diagnosis, 97% of papillary thyroid cancer patients are alive and cancer-free. However, curability depends heavily on the specific type, how far it has spread, and a few biological factors that influence how well the cancer responds to treatment.
Survival Rates by Type
Thyroid cancer is not one disease. There are four main types, and they behave very differently. The two most common, papillary and follicular, are classified as “differentiated” thyroid cancers. They grow slowly, respond well to treatment, and are highly curable. Papillary thyroid cancer accounts for roughly 80% of all cases, and follicular makes up another 10 to 15%.
Here’s how five-year survival breaks down by type, based on data from people diagnosed between 2015 and 2021:
- Papillary: greater than 99% overall. Even when it has spread to nearby lymph nodes, the rate is still 99%. When it reaches distant organs, survival drops to 71%, which is still relatively high for a cancer with distant spread.
- Follicular: 98% overall. Regional spread: 97%. Distant spread: 62%.
- Medullary: 93% overall. This type doesn’t respond to some of the standard treatments used for differentiated cancers, but it’s still curable when caught early (greater than 99% for localized disease). Distant spread brings the rate to 50%.
- Anaplastic: 10% overall. This is the rare and aggressive outlier. It grows fast, and localized disease still carries only a 45% five-year survival rate. Once it spreads beyond the thyroid region, the rate falls to 5%, with a median survival time of about 7.6 months.
For the vast majority of people reading this, the numbers are reassuring. Roughly 9 out of 10 thyroid cancers are the differentiated type, and those carry some of the highest survival rates of any cancer.
What “Cured” Actually Means
Doctors are cautious about using the word “cured” with any cancer. Instead, they typically classify your status after treatment into categories based on blood tests and imaging. The best outcome is called an “excellent response,” meaning there’s no detectable cancer on scans and your blood markers are at levels consistent with being cancer-free.
After a total thyroidectomy (complete removal of the thyroid), doctors track a protein called thyroglobulin in your blood. Since this protein is produced by thyroid tissue, its level should drop to near zero once the gland is gone. A level below 1 to 2.5 ng/mL generally signals that no significant thyroid tissue, cancerous or otherwise, remains. One study found that 97.9% of patients had thyroglobulin at or below 1 ng/mL at a median follow-up of five years. For most patients, this is effectively the blood test that confirms a cure.
For medullary thyroid cancer, which arises from different cells, doctors track a hormone called calcitonin instead. In patients who are surgically cured, calcitonin levels begin dropping rapidly within the first hour after surgery. Normal levels within the first few weeks suggest remission, though elevated levels right after surgery don’t necessarily mean the cancer persists.
How Treatment Works
The primary treatment for nearly all thyroid cancers is surgery, either removing the entire thyroid or just the affected lobe. For differentiated thyroid cancers, this alone is often curative, particularly for small, localized tumors.
Many patients also receive radioactive iodine therapy after surgery. Thyroid cells naturally absorb iodine, so a radioactive form of it can seek out and destroy any remaining thyroid cancer cells throughout the body. This treatment reduces the relative risk of recurrence by about 53%, making it particularly valuable for patients whose cancer has spread to lymph nodes or who have other higher-risk features.
Anaplastic thyroid cancer is the exception. It doesn’t respond to radioactive iodine. Treatment typically involves a combination of radiation, chemotherapy, and newer targeted therapies or immunotherapy. Recent data shows that patients who receive immunotherapy or targeted therapy have statistically significant improvements in survival compared to those who don’t, though outcomes for this type remain poor overall.
What Affects Your Odds of Recurrence
Even among the highly curable types, some thyroid cancers come back. Understanding the risk factors helps explain why some patients need closer monitoring than others.
Tumor size matters. For small papillary thyroid cancers, the 10-year recurrence rate for tumors under 1.8 cm is about 7.7%. For tumors between 1.8 and 2.0 cm, it jumps to 17.2%. The number of affected lymph nodes also plays a role: patients with zero or one positive lymph node had a 10-year recurrence rate of just 4%, while those with two or more had a rate of 16.8%.
Age is a surprisingly powerful factor. The cancer staging system uses age 55 as a dividing line for risk. Patients under 55 with papillary thyroid cancer are almost never staged higher than stage II, no matter how advanced the disease appears. That’s because younger patients have dramatically better outcomes. In one study, none of the patients under 55 had distant metastases, while 19 patients over 55 did. Patients over 55 were also more than five times as likely to have locally advanced disease.
Genetic Factors That Change the Picture
Some thyroid cancers carry genetic mutations that make them harder to treat. Two mutations in particular, known as BRAF V600E and TERT, have a significant impact when they occur together. Patients with both mutations had a 10.4-fold higher risk of recurrence compared to those without either one.
Perhaps more importantly, these co-mutations can cause the cancer to stop responding to radioactive iodine therapy, which is one of the most effective tools against differentiated thyroid cancer. Patients with both mutations were nearly five times more likely to lose the ability to absorb radioactive iodine, making the cancer harder to eliminate after surgery. The BRAF mutation alone, which is actually quite common in papillary thyroid cancer, did not significantly affect radioactive iodine response on its own. It’s the combination that creates the problem.
Not every patient is tested for these mutations, but they’re increasingly used to guide decisions about how aggressively to treat and how closely to monitor someone after initial surgery.
Long-Term Outlook
A large study tracking nearly 6,000 papillary thyroid cancer patients over decades found overall survival rates of 97% at 10 years, 95% at 15 years, and 90% at 20 years. When looking only at deaths caused by the cancer itself (rather than other causes), 99% of patients were alive at both 10 and 15 years, and 97% at 20 years. These numbers confirm that for the vast majority of patients, papillary thyroid cancer behaves more like a chronic, manageable condition than a life-threatening illness.
After treatment, you’ll have regular blood tests and neck ultrasounds, typically every 6 to 12 months initially and less frequently over time. If your thyroglobulin stays undetectable and imaging remains clean, your doctors will gradually reclassify your risk downward. Most patients reach a point where monitoring becomes routine rather than anxiety-driven, often within the first few years. For the small percentage whose cancer does recur, it’s usually treatable with additional surgery or radioactive iodine, and many achieve lasting remission a second time.